Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial

Table 2

Changes in clinical characteristics and laboratory indices in the gemigliptin group from baseline to month 6.

	Baseline	Month 6	Mean difference	value
Body weight (kg)				0.622
Body mass index (kg/m^2)				0.673
Mean arterial blood pressure				0.080
Hemoglobin (g/dL)				0.018
Estimated GFR (mL/min/1.73 m^2)				0.340
BUN (mg/dL)				0.189
Serum creatinine (mg/dL)				0.018
Fasting plasma glucose (mg/dL)				<0.001
Hemoglobin A1C (%)				<0.001
Serum potassium (mEq/L)				0.141
Serum magnesium (mg/dL)				0.128
Serum calcium (mg/dL)				0.037
Serum phosphate (mg/dL)				0.105
Serum albumin (g/dL)				0.379
Urine protein, 24 hours (g/day)				0.983
Coronary artery calcium score				0.180
CAVI				0.085
Serum myeloperoxidase (μg/L)				0.501
Serum osteopontin (ng/mL)				0.179
Serum bone alkaline phosphatase (μg/L)				<0.001
Urine NGAL (ng/mg creatinine)				0.412
Urine Kim (ng/mg creatinine)				0.023
Urine LFABP (μg/mg creatinine)				<0.001

Data are presented as the . CAVI: cardio-ankle vascular index; LFABP: liver acid-binding protein; NGAL: neutrophil gelatinase-associated lipocalin; Kim-1: kidney injury molecule-1.